Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.861,4380,DB00176,Fluvoxamine
,17417072,concentration-to-dose ratio,"A post-hoc analysis revealed that FLV concentration-to-dose ratio was significantly higher in the TT genotype group as compared with the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.861 vs 0.434, P = 0.026).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4381,DB00176,Fluvoxamine
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.618,4382,DB00176,Fluvoxamine
,17417072,concentration-to-dose ratio,"FLV concentration-to-dose ratio was significantly higher in the CT + TT genotype group than the CC genotype group at the 200 mg/d dose (median value of concentration-to-dose ratio (ng/mL)/(mg/d), 0.618 vs 0.434, P = 0.031).",Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17417072/),[ml·ng] / [d·mg],0.434,4383,DB00176,Fluvoxamine
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,42.8,5359,DB00176,Fluvoxamine
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,81.9,5360,DB00176,Fluvoxamine
,8005185,apparent half-life,The mean apparent half-life of alprazolam was increased from 20 h to 34 h after fluvoxamine co-administration.,A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8005185/),h,20,6853,DB00176,Fluvoxamine
,8005185,apparent half-life,The mean apparent half-life of alprazolam was increased from 20 h to 34 h after fluvoxamine co-administration.,A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8005185/),h,34,6854,DB00176,Fluvoxamine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB00176,Fluvoxamine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB00176,Fluvoxamine
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB00176,Fluvoxamine
,10445377,AUC,"In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2.58 from 780.8 ng/ml per hour to 2218.0 ng/ml per hour (P<0.001).",In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445377/),[ng] / [h·ml],780.8,15626,DB00176,Fluvoxamine
,10445377,AUC,"In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2.58 from 780.8 ng/ml per hour to 2218.0 ng/ml per hour (P<0.001).",In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445377/),[ng] / [h·ml],2218.0,15627,DB00176,Fluvoxamine
,21985609,peak plasma concentrations (C(max)),"4. In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 56.4 ± 25.6 ng/mL (zolpidem alone) and 67.3 ± 25.8 ng/mL (zolpidem after pretreatment with fluvoxamine).",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[ng] / [ml],56.4,16874,DB00176,Fluvoxamine
,21985609,peak plasma concentrations (C(max)),"4. In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 56.4 ± 25.6 ng/mL (zolpidem alone) and 67.3 ± 25.8 ng/mL (zolpidem after pretreatment with fluvoxamine).",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[ng] / [ml],67.3,16875,DB00176,Fluvoxamine
,21985609,t(max),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,0.83,16876,DB00176,Fluvoxamine
,21985609,t(max),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,1.26,16877,DB00176,Fluvoxamine
,21985609,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[h·ng] / [ml],200.9,16878,DB00176,Fluvoxamine
,21985609,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[h·ng] / [ml],512.0,16879,DB00176,Fluvoxamine
,21985609,half-life,The half-life of zolpidem was 2.24 ± 0.81 h when given alone and 4.99 ± 2.92 h after pretreatment with fluvoxamine.,Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,2.24,16880,DB00176,Fluvoxamine
,21985609,half-life,The half-life of zolpidem was 2.24 ± 0.81 h when given alone and 4.99 ± 2.92 h after pretreatment with fluvoxamine.,Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,4.99,16881,DB00176,Fluvoxamine
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB00176,Fluvoxamine
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB00176,Fluvoxamine
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB00176,Fluvoxamine
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB00176,Fluvoxamine
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB00176,Fluvoxamine
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.22,29064,DB00176,Fluvoxamine
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.020,29065,DB00176,Fluvoxamine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"1,583.05",29235,DB00176,Fluvoxamine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"2,111.55",29236,DB00176,Fluvoxamine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"5,754.71",29237,DB00176,Fluvoxamine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"6,293.17",29238,DB00176,Fluvoxamine
,16633150,occupancies,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),%,72.9,35934,DB00176,Fluvoxamine
,16633150,occupancies,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),%,50.3,35935,DB00176,Fluvoxamine
,16633150,occupancies,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),%,24.7,35936,DB00176,Fluvoxamine
,16633150,plasma concentrations,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),[ng] / [ml],13.9,35937,DB00176,Fluvoxamine
,16633150,plasma concentrations,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),[ng] / [ml],5.1,35938,DB00176,Fluvoxamine
,16633150,plasma concentrations,"Mean 5-HTT occupancies were 72.9% +/- 4.9% at 5 hours, 50.3% +/- 11.0% at 26 hours, and 24.7% +/- 15.3% at 53 hours, and plasma concentrations were 13.9 +/- 5.5 ng/mL at 5 hours, 5.1 +/- 3.2 ng/mL at 26 hours, and 1.5 +/- 1.7 ng/mL at 53 hours.",Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633150/),[ng] / [ml],1.5,35939,DB00176,Fluvoxamine
,15665745,recovery,Average recovery was about 100% for both substances.,A sensitive HPLC method for the determination of fluoxetine and norfluoxetine in human plasma with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15665745/),%,100,36868,DB00176,Fluvoxamine
,9501749,elimination half-lives,"Elimination of fluvoxamine in the brain and plasma was optimally described by first-order kinetics; the mean elimination half-lives were 58 hours and 26 hours, respectively.",Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9501749/),h,58,40827,DB00176,Fluvoxamine
,9501749,elimination half-lives,"Elimination of fluvoxamine in the brain and plasma was optimally described by first-order kinetics; the mean elimination half-lives were 58 hours and 26 hours, respectively.",Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9501749/),h,26,40828,DB00176,Fluvoxamine
,7992822,elimination half-lives,"The selective serotonin reuptake inhibitors (SSRIs)--paroxetine, sertraline, and fluvoxamine--have elimination half-lives of 15-26 hours.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,15-26,43464,DB00176,Fluvoxamine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-6,43465,DB00176,Fluvoxamine
,7992822,half-life,"The extended half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days), results in an extended time to steady-state and a prolonged washout period when dosing is discontinued.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),d,4-16,43466,DB00176,Fluvoxamine
,7992822,half-lives,"Venlafaxine and nefazodone have short half-lives, 2-5 hours, and are dosed > or = 2 times daily.",Pharmacokinetics of the newer antidepressants: clinical relevance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7992822/),h,2-5,43467,DB00176,Fluvoxamine
,25851638,absolute bioavailability,"Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here.","Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851638/),%,38,47044,DB00176,Fluvoxamine
,11180037,total clearance,"During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],845,48724,DB00176,Fluvoxamine
,11180037,total clearance,"During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],688,48725,DB00176,Fluvoxamine
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],901,48726,DB00176,Fluvoxamine
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],318,48727,DB00176,Fluvoxamine
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],723,48728,DB00176,Fluvoxamine
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],457,48729,DB00176,Fluvoxamine
,17596106,plasma clearance,"Roflumilast plasma clearance decreased by a factor of 2.6, from 9.06 L/h (reference) to 3.53 L/h (test).",Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596106/),[l] / [h],9.06,50665,DB00176,Fluvoxamine
,17596106,plasma clearance,"Roflumilast plasma clearance decreased by a factor of 2.6, from 9.06 L/h (reference) to 3.53 L/h (test).",Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596106/),[l] / [h],3.53,50666,DB00176,Fluvoxamine
,19557140,maximum plasma concentration,"In preclinical studies, the maximum plasma concentration and bioavailability of an extended-release (CR) formulation of fluvoxamine were, respectively, 38% and 16% lower than those of the standard (ie, non-CR) formulation.",Management of obsessive-compulsive disorder with fluvoxamine extended release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19557140/),%,38,51637,DB00176,Fluvoxamine
,19557140,bioavailability,"In preclinical studies, the maximum plasma concentration and bioavailability of an extended-release (CR) formulation of fluvoxamine were, respectively, 38% and 16% lower than those of the standard (ie, non-CR) formulation.",Management of obsessive-compulsive disorder with fluvoxamine extended release. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19557140/),%,16,51638,DB00176,Fluvoxamine
,15664751,flow rate,"The mobile phase for separation consisted of phosphate buffer (0.02 M, pH 4.6), acetonitrile and perchloric acid (60%) (62.4:37.5:0.1, v/v/v) and was delivered at a flow rate of 0.6 ml/min.",Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664751/),[ml] / [min],0.6,52161,DB00176,Fluvoxamine
,15664751,limit of,"The limit of quantification was 1.2 and 0.9 ng/ml for fluvoxamine and fluvoxamino acid, respectively.",Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664751/),[ng] / [ml],1.2,52162,DB00176,Fluvoxamine
,15664751,limit of,"The limit of quantification was 1.2 and 0.9 ng/ml for fluvoxamine and fluvoxamino acid, respectively.",Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664751/),[ng] / [ml],0.9,52163,DB00176,Fluvoxamine
,11240973,area under the concentration-time curve,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],10.4,53241,DB00176,Fluvoxamine
,11240973,area under the concentration-time curve,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],6.70,53242,DB00176,Fluvoxamine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[h·μg] / [ml],6.70,53243,DB00176,Fluvoxamine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[μg] / [ml],0.623,53244,DB00176,Fluvoxamine
,11240973,serum peak concentration,"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10.4 +/- 4.85 versus 6.70 +/- 3.21 microg x h/mL, P =.006 and 0.623 +/- 0.133 versus 0.536 +/- 0.164 microg/mL, P =.008, respectively).",Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240973/),[μg] / [ml],0.536,53245,DB00176,Fluvoxamine
,1485372,area under the curve (AUC),The area under the curve (AUC) of fluvoxamine tended to be larger following multiple (873 ng.h/ml) as compared to single-dose administration (652 ng.h/ml).,Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485372/),[h·ng] / [ml],873,53339,DB00176,Fluvoxamine
,1485372,area under the curve (AUC),The area under the curve (AUC) of fluvoxamine tended to be larger following multiple (873 ng.h/ml) as compared to single-dose administration (652 ng.h/ml).,Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485372/),[h·ng] / [ml],652,53340,DB00176,Fluvoxamine
,1485372,terminal half-life,Also the terminal half-life after chronic dosing (22 +/- 6 h) tended to be longer than after single dosing.,Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485372/),h,22,53341,DB00176,Fluvoxamine
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],0.86,53686,DB00176,Fluvoxamine
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],1.4,53687,DB00176,Fluvoxamine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00176,Fluvoxamine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00176,Fluvoxamine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00176,Fluvoxamine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],12.1,57491,DB00176,Fluvoxamine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],4.85,57492,DB00176,Fluvoxamine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],9.83,57493,DB00176,Fluvoxamine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],5.06,57494,DB00176,Fluvoxamine
,14749694,terminal half-lives,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],4.21,57495,DB00176,Fluvoxamine
,14749694,terminal half-lives,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],3.65,57496,DB00176,Fluvoxamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],237,58611,DB00176,Fluvoxamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],174,58612,DB00176,Fluvoxamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],100,58613,DB00176,Fluvoxamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],237,58614,DB00176,Fluvoxamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],174,58615,DB00176,Fluvoxamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],100,58616,DB00176,Fluvoxamine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,1 and 4,62758,DB00176,Fluvoxamine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,7 and 15,62759,DB00176,Fluvoxamine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,21,62760,DB00176,Fluvoxamine
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,36,62761,DB00176,Fluvoxamine
,11049910,elimination half-life (t(1/2)),"Fluvoxamine increased the area under the drug plasma concentration-time curve (AUC) of ropivacaine 3.7-fold (P: < 0.001), prolonged the elimination half-life (t(1/2)) from 2.3 to 7.4 h (P: < 0.01), and decreased the clearance by 77% (P: < 0.001).","The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049910/),h,2.3,67356,DB00176,Fluvoxamine
,11049910,elimination half-life (t(1/2)),"Fluvoxamine increased the area under the drug plasma concentration-time curve (AUC) of ropivacaine 3.7-fold (P: < 0.001), prolonged the elimination half-life (t(1/2)) from 2.3 to 7.4 h (P: < 0.01), and decreased the clearance by 77% (P: < 0.001).","The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049910/),h,7.4,67357,DB00176,Fluvoxamine
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00176,Fluvoxamine
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00176,Fluvoxamine
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00176,Fluvoxamine
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00176,Fluvoxamine
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00176,Fluvoxamine
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00176,Fluvoxamine
,12695344,"K(i,ub)","K(i,total) values varied with microsomal protein concentration, whereas the corresponding K(i,ub) values were within a narrow range (70-80 nM).",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,70-80,71464,DB00176,Fluvoxamine
,12695344,K(i)iv,"The mean (+/-S.D.) values of K(i)iv based on total and unbound plasma concentrations were 13.5 +/- 5.6 and 1.9 +/- 1.1 nM, respectively.",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,13.5,71465,DB00176,Fluvoxamine
,12695344,K(i)iv,"The mean (+/-S.D.) values of K(i)iv based on total and unbound plasma concentrations were 13.5 +/- 5.6 and 1.9 +/- 1.1 nM, respectively.",Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695344/),nM,1.9,71466,DB00176,Fluvoxamine
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.31,72340,DB00176,Fluvoxamine
,9174682,areas under the serum concentration-time curve,Poor metabolizers of dextromethorphan had significantly higher areas under the serum concentration-time curve than extensive metabolizers of dextromethorphan (mean 1.31 vs 1.00 mumol.h.l-1).,Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174682/),[h·μM] / [l],1.00,72341,DB00176,Fluvoxamine
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],177,75178,DB00176,Fluvoxamine
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],121,75179,DB00176,Fluvoxamine
,11719727,K(i),"In vitro K(i) values based on total inhibitor concentrations were 177 +/- 56 nmol/L, 121 +/- 21 nmol/L, and 52 +/- 13 nmol/L in human liver microsomes with 1 mg/ml protein and 0.5 mg/ml protein and in supersomes with 0.3 mg/ml protein, respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],52,75180,DB00176,Fluvoxamine
,11719727,K(i),"The corresponding in vitro K(i) values based on unbound fluvoxamine concentrations were 35 nmol/L, 36 nmol/L, and 36 nmol/L.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],35,75181,DB00176,Fluvoxamine
,11719727,K(i),"The corresponding in vitro K(i) values based on unbound fluvoxamine concentrations were 35 nmol/L, 36 nmol/L, and 36 nmol/L.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],36,75182,DB00176,Fluvoxamine
,11719727,K(i)iv,"Mean values for K(i)iv based on total and unbound plasma concentrations at steady state were 25.3 nmol/L (range, 14-39 nmol/L) and 3.6 nmol/L (range, 2.4-5.9 nmol/L), respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],25.3,75183,DB00176,Fluvoxamine
,11719727,K(i)iv,"Mean values for K(i)iv based on total and unbound plasma concentrations at steady state were 25.3 nmol/L (range, 14-39 nmol/L) and 3.6 nmol/L (range, 2.4-5.9 nmol/L), respectively.",Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719727/),[nM] / [l],3.6,75184,DB00176,Fluvoxamine
,8453824,peak plasma concentrations,"Geometric mean values for peak plasma concentrations and area under the plasma concentration-time curves (AUC) were 39 micrograms/L and 1338 micrograms.h/L, respectively.",Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453824/),[μg] / [l],39,79142,DB00176,Fluvoxamine
,8453824,area under the plasma concentration-time curves (AUC),"Geometric mean values for peak plasma concentrations and area under the plasma concentration-time curves (AUC) were 39 micrograms/L and 1338 micrograms.h/L, respectively.",Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453824/),[h·μg] / [l],1338,79143,DB00176,Fluvoxamine
,8453824,elimination half-life (t1/2),"Mean (+/- SD) elimination half-life (t1/2) was 25 +/- 11h, and increased with higher plasma bilirubin levels, although no relationship between bilirubin and AUC was observed.",Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453824/),h,25,79144,DB00176,Fluvoxamine
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB00176,Fluvoxamine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB00176,Fluvoxamine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB00176,Fluvoxamine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB00176,Fluvoxamine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB00176,Fluvoxamine
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB00176,Fluvoxamine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB00176,Fluvoxamine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB00176,Fluvoxamine
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB00176,Fluvoxamine
,15845683,elimination half-life,Fluvoxamine alone decreased the clearance of lidocaine by 41% (P < 0.001) and prolonged its elimination half-life from 2.6 to 3.5 h (P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,2.6,83700,DB00176,Fluvoxamine
,15845683,elimination half-life,Fluvoxamine alone decreased the clearance of lidocaine by 41% (P < 0.001) and prolonged its elimination half-life from 2.6 to 3.5 h (P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,3.5,83701,DB00176,Fluvoxamine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,4.3,83702,DB00176,Fluvoxamine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,2.6,83703,DB00176,Fluvoxamine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,3.5,83704,DB00176,Fluvoxamine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,1.5,84231,DB00176,Fluvoxamine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,4,84232,DB00176,Fluvoxamine
,9090339,brain-to-plasma ratio at steady state,The mean brain-to-plasma ratio at steady state was 24 to 1.,19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9090339/),,24 to 1,86089,DB00176,Fluvoxamine
,9090339,T1,Brain fluvoxamine T1 values from 140 to 230 msec were observed.,19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9090339/),ms,140 to 230,86090,DB00176,Fluvoxamine
,17710515,passive influx into (k in),The model resulted in precise estimates of the parameters describing passive influx into (k in) of 0.16 min(-1) and efflux from the shallow brain compartment (k out) of 0.019 min(-1) and the fluvoxamine concentration at which 50% of the maximum active efflux (C 50) is reached of 710 ng.,Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17710515/),1/[min],0.16,86158,DB00176,Fluvoxamine
,17710515,efflux from the shallow brain compartment (k out),The model resulted in precise estimates of the parameters describing passive influx into (k in) of 0.16 min(-1) and efflux from the shallow brain compartment (k out) of 0.019 min(-1) and the fluvoxamine concentration at which 50% of the maximum active efflux (C 50) is reached of 710 ng.,Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17710515/),1/[min],0.019,86159,DB00176,Fluvoxamine
,1801963,plasma AUC,The plasma AUC of fluvoxamine was on average 7 per cent lower in the fed than in the fasted state.,Bioavailability of fluvoxamine given with and without food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1801963/),%,7,88929,DB00176,Fluvoxamine
,7586931,areas under the serum concentration-time curve,"The smokers had significantly lower areas under the serum concentration-time curve and significantly lower maximal serum concentrations than the nonsmokers (mean +/- SD, 771 +/- 346 versus 1110 +/- 511 nmol.hr.L-1 [p = 0.012] and 39.1 +/- 17.3 versus 57.7 +/- 21.5 nmol.L-1 [p = 0.012], respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[h·nM] / [l],771,95206,DB00176,Fluvoxamine
,7586931,areas under the serum concentration-time curve,"The smokers had significantly lower areas under the serum concentration-time curve and significantly lower maximal serum concentrations than the nonsmokers (mean +/- SD, 771 +/- 346 versus 1110 +/- 511 nmol.hr.L-1 [p = 0.012] and 39.1 +/- 17.3 versus 57.7 +/- 21.5 nmol.L-1 [p = 0.012], respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[h·nM] / [l],1110,95207,DB00176,Fluvoxamine
,7586931,maximal serum concentrations,"The smokers had significantly lower areas under the serum concentration-time curve and significantly lower maximal serum concentrations than the nonsmokers (mean +/- SD, 771 +/- 346 versus 1110 +/- 511 nmol.hr.L-1 [p = 0.012] and 39.1 +/- 17.3 versus 57.7 +/- 21.5 nmol.L-1 [p = 0.012], respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[nM] / [l],39.1,95208,DB00176,Fluvoxamine
,7586931,maximal serum concentrations,"The smokers had significantly lower areas under the serum concentration-time curve and significantly lower maximal serum concentrations than the nonsmokers (mean +/- SD, 771 +/- 346 versus 1110 +/- 511 nmol.hr.L-1 [p = 0.012] and 39.1 +/- 17.3 versus 57.7 +/- 21.5 nmol.L-1 [p = 0.012], respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[nM] / [l],57.7,95209,DB00176,Fluvoxamine
,7586931,terminal elimination half-life,"The terminal elimination half-life did not differ significantly between smokers and nonsmokers (10.1 +/- 1.9 and 10.7 +/- 2.3 hours, respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),h,10.1,95210,DB00176,Fluvoxamine
,7586931,terminal elimination half-life,"The terminal elimination half-life did not differ significantly between smokers and nonsmokers (10.1 +/- 1.9 and 10.7 +/- 2.3 hours, respectively).",Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),h,10.7,95211,DB00176,Fluvoxamine
,7586931,oral clearance,The oral clearance was high among both smokers (4.1 +/- 1.9 L.min-1) and nonsmokers (3.3 +/- 2.7 L.min-1; difference not significant).,Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[l] / [min],4.1,95212,DB00176,Fluvoxamine
,7586931,oral clearance,The oral clearance was high among both smokers (4.1 +/- 1.9 L.min-1) and nonsmokers (3.3 +/- 2.7 L.min-1; difference not significant).,Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586931/),[l] / [min],3.3,95213,DB00176,Fluvoxamine
,1939476,limit of detection,"The estimated limit of detection is 0.5 ng/ml, and selected drugs checked for coadministration show no analytical interference.",Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1939476/),[ng] / [ml],0.5,97756,DB00176,Fluvoxamine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.13,105121,DB00176,Fluvoxamine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.27,105122,DB00176,Fluvoxamine
,8685072,MR,The mean MR increased from 0.13 to 0.27 (P<0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P<0.05).,"Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0,105123,DB00176,Fluvoxamine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.24,105124,DB00176,Fluvoxamine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.34,105125,DB00176,Fluvoxamine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.33,105126,DB00176,Fluvoxamine
,8685072,S/R,"The mean S/R increased from 0.24 to 0.34 (P<0.05) with fluoxetine, and from 0.33 to 0.58 (P<0.002) with fluvoxamine.","Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685072/),,0.58,105127,DB00176,Fluvoxamine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],58,112118,DB00176,Fluvoxamine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],87,112119,DB00176,Fluvoxamine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],223,112120,DB00176,Fluvoxamine
,8738315,Plasma,Plasma levels of clomipramine and desmethylclomipramine changed from 58 ng/ml and 87 ng/ml to 223 ng/ml and 49 ng/ml respectively one week after addition of fluvoxamine.,Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738315/),[ng] / [ml],49,112121,DB00176,Fluvoxamine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,22.8,113388,DB00176,Fluvoxamine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,40.5,113389,DB00176,Fluvoxamine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [h·kg],1.02,113390,DB00176,Fluvoxamine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [h·kg],0.28,113391,DB00176,Fluvoxamine
,29101463,area under the plasma concentration-time curve (AUC0-72h),"At steady state the geometric mean for dovitinib (coefficient of variation%) of the area under the plasma concentration-time curve (AUC0-72h) and maximum concentration (C max) were 2880 ng/mL h (47%) and 144 ng/mL (41%), respectively.",A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101463/),[ng] / [h·ml],2880,123693,DB00176,Fluvoxamine
,29101463,maximum concentration (C max),"At steady state the geometric mean for dovitinib (coefficient of variation%) of the area under the plasma concentration-time curve (AUC0-72h) and maximum concentration (C max) were 2880 ng/mL h (47%) and 144 ng/mL (41%), respectively.",A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101463/),[ng] / [ml],144,123694,DB00176,Fluvoxamine
,29101463,AUC0-72h,"Following administration of dovitinib in combination with fluvoxamine the geometric mean of dovitinib AUC0-72h and C max were 8290 ng/mL h (60%) and 259 ng/mL (45%), respectively.",A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101463/),[ng] / [h·ml],8290,123695,DB00176,Fluvoxamine
,29101463,C max,"Following administration of dovitinib in combination with fluvoxamine the geometric mean of dovitinib AUC0-72h and C max were 8290 ng/mL h (60%) and 259 ng/mL (45%), respectively.",A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101463/),[ng] / [ml],259,123696,DB00176,Fluvoxamine
,10989270,steady-state brain concentrations,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),μM,12,124549,DB00176,Fluvoxamine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,10,124550,DB00176,Fluvoxamine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),μM,13,124551,DB00176,Fluvoxamine
,10989270,brain-to-plasma concentration ratios,Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,10,124552,DB00176,Fluvoxamine
,10989270,brain elimination half-life,Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),h,79,124553,DB00176,Fluvoxamine
,10989270,brain elimination half-life,Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2).,Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),h,382,124554,DB00176,Fluvoxamine
,10989270,brain-to-plasma-half-life-ratio,"Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 +/- 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 +/- 0.3; n = 2).",Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,2.2,124555,DB00176,Fluvoxamine
,10989270,brain-to-plasma-half-life-ratio,"Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 +/- 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 +/- 0.3; n = 2).",Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10989270/),,1.0,124556,DB00176,Fluvoxamine
,11309547,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.0 to 3.3 hours (P <.0001) by fluconazole.,Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.0,125945,DB00176,Fluvoxamine
,11309547,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.0 to 3.3 hours (P <.0001) by fluconazole.,Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,3,125946,DB00176,Fluvoxamine
,11309547,elimination half-life,"However, the mean peak plasma concentration of glimepiride was 143% (P <.05) of the control and the elimination half-life was prolonged from 2.0 to 2.3 hours (P <.01) by fluvoxamine.",Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.0,125947,DB00176,Fluvoxamine
,11309547,elimination half-life,"However, the mean peak plasma concentration of glimepiride was 143% (P <.05) of the control and the elimination half-life was prolonged from 2.0 to 2.3 hours (P <.01) by fluvoxamine.",Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.3,125948,DB00176,Fluvoxamine
,22202224,plasma protein binding,"The plasma protein binding of FLV was around 83% and 95% in control and HL rats, respectively, whereas the FLV recoveries in triglyceride-rich lipoprotein fractions were increased in HL.",Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22202224/),%,83,126402,DB00176,Fluvoxamine
,22202224,plasma protein binding,"The plasma protein binding of FLV was around 83% and 95% in control and HL rats, respectively, whereas the FLV recoveries in triglyceride-rich lipoprotein fractions were increased in HL.",Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22202224/),%,95,126403,DB00176,Fluvoxamine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),mg,2.67,128245,DB00176,Fluvoxamine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),[ng] / [ml],1.42,128246,DB00176,Fluvoxamine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),mg,18.6,128247,DB00176,Fluvoxamine
,12695316,effective dose (ED50),"Estimated median effective dose (ED50) of clomipramine hydrochloride was 2.67 mg for oral dose and 1.42 ng/mL for plasma concentration; those of fluvoxamine maleate were 18.6 mg and 4.19 ng/mL, respectively.",High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695316/),[ng] / [ml],4.19,128248,DB00176,Fluvoxamine
,17134886,CL,"Body weight was included as a covariate and mean population PK parameters for CL, V(1), V(2), Q(2), V(3) and Q(3) were 25.1 ml/min, 256 ml, 721 ml, 30.3 ml/min, 136 ml and 1.0 ml/min, respectively.",Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17134886/),[ml] / [min],25.1,128632,DB00176,Fluvoxamine
,17134886,Q(3),"Body weight was included as a covariate and mean population PK parameters for CL, V(1), V(2), Q(2), V(3) and Q(3) were 25.1 ml/min, 256 ml, 721 ml, 30.3 ml/min, 136 ml and 1.0 ml/min, respectively.",Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17134886/),[ml] / [min],1.0,128633,DB00176,Fluvoxamine
,9068931,half-life (t1/2),Most SSRIs have a half-life (t1/2) of approximately 1 day.,Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,1,129521,DB00176,Fluvoxamine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,2 to 4,129522,DB00176,Fluvoxamine
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,7 to 15,129523,DB00176,Fluvoxamine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00176,Fluvoxamine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00176,Fluvoxamine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,81 to 118,129741,DB00176,Fluvoxamine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,73 to 95,129742,DB00176,Fluvoxamine
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,39 to 66,129743,DB00176,Fluvoxamine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB00176,Fluvoxamine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB00176,Fluvoxamine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB00176,Fluvoxamine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB00176,Fluvoxamine
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],1282,142096,DB00176,Fluvoxamine
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],782,142097,DB00176,Fluvoxamine
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],222,142098,DB00176,Fluvoxamine
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],97,142099,DB00176,Fluvoxamine
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],33,142100,DB00176,Fluvoxamine
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],11,142101,DB00176,Fluvoxamine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],47,143268,DB00176,Fluvoxamine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],110,143269,DB00176,Fluvoxamine
,21366359,elimination half-life,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),h,10-12,143270,DB00176,Fluvoxamine
,21366359,volume of distribution,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),l,1640,143271,DB00176,Fluvoxamine
,8844419,Recoveries,Recoveries ranged from 50 to 66% for the three compounds.,Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8844419/),%,50 to 66,145913,DB00176,Fluvoxamine
,1531816,elimination half-life,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,2 to 3,152373,DB00176,Fluvoxamine
,1531816,half-lives,"With the exception of fluoxetine, which has an elimination half-life of 2 to 3 days, the other drugs have half-lives of about 1 day.",Pharmacokinetics of the selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531816/),d,1,152374,DB00176,Fluvoxamine
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB00176,Fluvoxamine
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB00176,Fluvoxamine
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB00176,Fluvoxamine
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB00176,Fluvoxamine
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB00176,Fluvoxamine
,9184622,half-life,"Fluvoxamine is well absorbed after oral administration, widely distributed in the body, and eliminated with a mean half-life of 15 hours and a range from 9 hours to 28 hours.",Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9184622/),h,15,154096,DB00176,Fluvoxamine
,9184622,half-life,"Fluvoxamine is well absorbed after oral administration, widely distributed in the body, and eliminated with a mean half-life of 15 hours and a range from 9 hours to 28 hours.",Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9184622/),h,28,154097,DB00176,Fluvoxamine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,17,154901,DB00176,Fluvoxamine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,50,154902,DB00176,Fluvoxamine
,17431033,K(m),The K(m) value for the formation of M1 was 23.8 microM in human liver microsomes.,Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,23.8,166307,DB00176,Fluvoxamine
,17431033,K(i),"The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,0.08,166308,DB00176,Fluvoxamine
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,3,166309,DB00176,Fluvoxamine
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,2 to 5,166310,DB00176,Fluvoxamine
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB00176,Fluvoxamine
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00176,Fluvoxamine
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,1.4,173884,DB00176,Fluvoxamine
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,53,173885,DB00176,Fluvoxamine
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,34.3,173886,DB00176,Fluvoxamine
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,23.1,173887,DB00176,Fluvoxamine
,16236038,apparent oral clearance,Fluvoxamine significantly reduced apparent oral clearance of caffeine (105 vs.,Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),,105,175340,DB00176,Fluvoxamine
,16236038,elimination half-life,"9.1 mL min(-1), P < 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6), and prolonged its elimination half-life (4.9 vs. 56 h, P < 0.01; mean difference: 51 h, 95% CI: 26-76).",Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),h,4.9,175341,DB00176,Fluvoxamine
,16236038,elimination half-life,"9.1 mL min(-1), P < 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6), and prolonged its elimination half-life (4.9 vs. 56 h, P < 0.01; mean difference: 51 h, 95% CI: 26-76).",Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),h,56,175342,DB00176,Fluvoxamine
,12352274,concentrations,Fluvoxamine concentrations were 48 +/- 26 ng/mL on week 1 and 83 +/- 47 ng/mL on week 8.,Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352274/),ng,48,177424,DB00176,Fluvoxamine
,17157470,flow rate,"The chromatographic conditions were as follows: Phenomenex C(18) (250 mm x 4.6 mm i.d., 5 microm) column, mobile phase consisting of acetonitrile/water (80:20 v/v) at a flow rate of 1 ml/min.",HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),[ml] / [min],1,182353,DB00176,Fluvoxamine
,17157470,limits of detection (LOD),The limits of detection (LOD) were 1.4 and 1 ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3.,HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),[ng] / [ml],1.4,182354,DB00176,Fluvoxamine
,17157470,limits of detection (LOD),The limits of detection (LOD) were 1.4 and 1 ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3.,HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),[ng] / [ml],1,182355,DB00176,Fluvoxamine
,17157470,signal-to-noise (S/N) ratio,The limits of detection (LOD) were 1.4 and 1 ng/ml for plasma and urine estimation at a signal-to-noise (S/N) ratio of 3.,HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),,3,182356,DB00176,Fluvoxamine
,17157470,limits of quantification (LOQ),"The limits of quantification (LOQ) were 5 and 2 ng/ml for plasma and urine, respectively.",HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),[ng] / [ml],5,182357,DB00176,Fluvoxamine
,17157470,limits of quantification (LOQ),"The limits of quantification (LOQ) were 5 and 2 ng/ml for plasma and urine, respectively.",HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),[ng] / [ml],2,182358,DB00176,Fluvoxamine
,17157470,extraction recoveries,"The extraction recoveries were found to be 96.66+/-0.69 and 96.73+/-2.17% for plasma and urine, respectively.",HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),%,96.66,182359,DB00176,Fluvoxamine
,17157470,extraction recoveries,"The extraction recoveries were found to be 96.66+/-0.69 and 96.73+/-2.17% for plasma and urine, respectively.",HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17157470/),%,96.73,182360,DB00176,Fluvoxamine
,9209244,area under the plasma concentration versus time curve (AUC),"Fluvoxamine caused a significant increase in tacrine area under the plasma concentration versus time curve (AUC): arythmetic mean, 27 (95% confidence interval [CI], 19 to 38) ng.hr/ml versus 224 (95% CI, 166 to 302) ng. hr/ml.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[h·ng] / [ml],27,188359,DB00176,Fluvoxamine
,9209244,area under the plasma concentration versus time curve (AUC),"Fluvoxamine caused a significant increase in tacrine area under the plasma concentration versus time curve (AUC): arythmetic mean, 27 (95% confidence interval [CI], 19 to 38) ng.hr/ml versus 224 (95% CI, 166 to 302) ng. hr/ml.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[h·ng] / [ml],224,188360,DB00176,Fluvoxamine
,9209244,apparent oral clearance,"Fluvoxamine caused a decrease in the apparent oral clearance of tacrine from 1683 +/- 802 to 200 +/- 106 L/hr (mean +/- SD), which was explained by a decrease in its nonrenal clearance.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[l] / [h],1683,188361,DB00176,Fluvoxamine
,9209244,apparent oral clearance,"Fluvoxamine caused a decrease in the apparent oral clearance of tacrine from 1683 +/- 802 to 200 +/- 106 L/hr (mean +/- SD), which was explained by a decrease in its nonrenal clearance.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[l] / [h],200,188362,DB00176,Fluvoxamine
,25558834,Chb,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),nM,100,195960,DB00176,Fluvoxamine
,25558834,maximal Chb -to-maximal Cb ratio,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,2.3,195961,DB00176,Fluvoxamine
,25558834,liver uptake,"Fluvoxamine and tacrine are known to exhibit relatively large F values despite having CLtot similar to or larger than hepatic blood flow, which may be because of the high liver uptake (almost 0.6) upon intravenous administration.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,0.6,195962,DB00176,Fluvoxamine
,12222750,hydroxylation index,Four PMs were identified with the omeprazole phenotype probe and had a mean +/- SD hydroxylation index of 1.335 +/- 0.271.,Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222750/),,1.335,196426,DB00176,Fluvoxamine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,23,199315,DB00176,Fluvoxamine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,60,199316,DB00176,Fluvoxamine
,10445388,Ki,"In vitro studies with control liver microsomes, as well as with microsomes of rats treated chronically with fluoxetine show that the changes in the thioridazine pharmacokinetics may be attributed to the competitive (N-demethylation, Ki = 23 microM) and mixed inhibition (2- and 5-sulfoxidation, Ki = 60 microM and 34 microM, respectively) of thioridazine metabolism by fluoxetine, and to the adaptive changes produced by chronic administration of fluoxetine, as reflected by inhibition of N-demethylation and formation of sulforidazine.",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,34,199317,DB00176,Fluvoxamine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,41,199318,DB00176,Fluvoxamine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,64,199319,DB00176,Fluvoxamine
,10445388,Ki,"Sertraline seemed to have a tendency to decrease thioridazine concentration in vivo, though in vitro studies showed that - like fluoxetine - it competitively or via mixed mechanism inhibited the three metabolic pathways of thioridazine (Ki = 41 microM, 64 microM and 47 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,47,199320,DB00176,Fluvoxamine
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,17,199321,DB00176,Fluvoxamine
,10445388,Ki,"In the case of fluvoxamine, a tendency to increase the thioridazine level was observed, which may be connected with the competitive or mixed inhibition of thioridazine N-demethylation and 2-sulfoxidation by the antidepressant (Ki = 17 microM and 167 microM, respectively).",The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445388/),μM,167,199322,DB00176,Fluvoxamine
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00176,Fluvoxamine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00176,Fluvoxamine
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00176,Fluvoxamine
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00176,Fluvoxamine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00176,Fluvoxamine
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00176,Fluvoxamine
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00176,Fluvoxamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00176,Fluvoxamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00176,Fluvoxamine
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00176,Fluvoxamine
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],1.67,203286,DB00176,Fluvoxamine
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],2.20,203287,DB00176,Fluvoxamine
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],12.1,203288,DB00176,Fluvoxamine
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],19.3,203289,DB00176,Fluvoxamine
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],0.680,203290,DB00176,Fluvoxamine
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],0.960,203291,DB00176,Fluvoxamine
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],17.6,203292,DB00176,Fluvoxamine
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],25.5,203293,DB00176,Fluvoxamine
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00176,Fluvoxamine
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00176,Fluvoxamine
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00176,Fluvoxamine
,19011672,AUCS/R ratio,The kinetic disposition of CITA was enantioselective in rats (AUCS/R ratio = 0.4).,"Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19011672/),,0.4,205323,DB00176,Fluvoxamine
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[ng] / [ml],882,206585,DB00176,Fluvoxamine
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],1214,206586,DB00176,Fluvoxamine
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],2762,206587,DB00176,Fluvoxamine
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212918,DB00176,Fluvoxamine
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,300",212919,DB00176,Fluvoxamine
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212920,DB00176,Fluvoxamine
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,600",212921,DB00176,Fluvoxamine
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,2.07,212922,DB00176,Fluvoxamine
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,7.49,212923,DB00176,Fluvoxamine
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.765,212924,DB00176,Fluvoxamine
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.256,212925,DB00176,Fluvoxamine
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[ml] / [h],72.1,214088,DB00176,Fluvoxamine
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [ml],"101,163",214089,DB00176,Fluvoxamine
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,15,214090,DB00176,Fluvoxamine
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,210,214091,DB00176,Fluvoxamine
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,28,214092,DB00176,Fluvoxamine
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,126,214093,DB00176,Fluvoxamine
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],5400,214094,DB00176,Fluvoxamine
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],6.56 × 10(10),214095,DB00176,Fluvoxamine
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],0.97,214096,DB00176,Fluvoxamine
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],132.50,214097,DB00176,Fluvoxamine
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,35,214098,DB00176,Fluvoxamine
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,1602,214099,DB00176,Fluvoxamine
,26008214,Bioavailability,Bioavailability of oral melatonin ranged from 9 to 33%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,9 to 33,214100,DB00176,Fluvoxamine
,26008214,Tmax,"Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin.",Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,50,214101,DB00176,Fluvoxamine
,26008214,T1/2,T1/2 was 45 min in both administration routes.,Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,45,214102,DB00176,Fluvoxamine
,26008214,Bioavailability,Bioavailability of oral melatonin was approximately 15%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,15,214103,DB00176,Fluvoxamine
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],354,219053,DB00176,Fluvoxamine
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],112,219054,DB00176,Fluvoxamine
,9834040,plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],302,219055,DB00176,Fluvoxamine
,9834040,half-life (t1/2),"The ropivacaine half-life (t1/2) of 1.9 hours was almost doubled during fluvoxamine administration and the plasma concentration at the end of infusion increased slightly, whereas the corresponding parameters after ketoconazole administration remained unchanged.",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),h,1.9,219056,DB00176,Fluvoxamine
,15905806,Cmax,"Enoxacin significantly increased the plasma concentrations at 2 hours (placebo versus enoxacin, mean+/-SD: 4.4+/-2.4 vs 7.0+/-4.1 ng/mL, P<0.05) and 3 hours (7.4+/-2.7 vs 11.2+/-3.8 ng/mL, P<0.01) and the Cmax (10.2+/-2.9 vs 11.6+/-4.0 ng/mL, P<0.05) of FLV.",Interaction study between enoxacin and fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905806/),[ng] / [ml],10.2,222246,DB00176,Fluvoxamine
,15905806,Cmax,"Enoxacin significantly increased the plasma concentrations at 2 hours (placebo versus enoxacin, mean+/-SD: 4.4+/-2.4 vs 7.0+/-4.1 ng/mL, P<0.05) and 3 hours (7.4+/-2.7 vs 11.2+/-3.8 ng/mL, P<0.01) and the Cmax (10.2+/-2.9 vs 11.6+/-4.0 ng/mL, P<0.05) of FLV.",Interaction study between enoxacin and fluvoxamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905806/),[ng] / [ml],11.6,222247,DB00176,Fluvoxamine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],107,226379,DB00176,Fluvoxamine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21,226380,DB00176,Fluvoxamine
,8807660,half-life,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),h,5 to 31,226381,DB00176,Fluvoxamine
,8807660,clearance,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],46 to 9,226382,DB00176,Fluvoxamine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21 to 9,226383,DB00176,Fluvoxamine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],14 to 6,226384,DB00176,Fluvoxamine
,28962699,plasma concentration ratio,"The model predicted a maternal-fetal plasma concentration ratio of 0.376 after repeated maternal administration of fluvoxamine, similar to the ratio for paroxetine.",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),,0.376,227409,DB00176,Fluvoxamine
,28962699,half-life,"However, if the mother ceased taking drug, the model predicted a half-life of fluvoxamine in fetal plasma of 35 h, which is longer than that of paroxetine (10 h).",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),h,35,227410,DB00176,Fluvoxamine
,28962699,half-life,"However, if the mother ceased taking drug, the model predicted a half-life of fluvoxamine in fetal plasma of 35 h, which is longer than that of paroxetine (10 h).",Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962699/),h,10,227411,DB00176,Fluvoxamine
,20233199,peak concentration,"Thus, peak concentration was about doubled {31 +/- 19 vs.",Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233199/),,31,227976,DB00176,Fluvoxamine
,20233199,area under the concentration-time curve,"15 +/- 9 ng ml(-1); difference [95% confidence interval (CI)] 16 (3, 29), P < 0.05}, and area under the concentration-time curve was almost three times higher [885 +/- 560 vs.",Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233199/),,885,227977,DB00176,Fluvoxamine
,20233199,oral clearance,"12.9 +/- 6.4 h; difference (95% CI) 8.2 (2.3, 14.1), P < 0.01], and oral clearance was halved (1.12 +/- 0.77 vs.",Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233199/),,1.12,227978,DB00176,Fluvoxamine
,9029748,total clearance,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],80,232162,DB00176,Fluvoxamine
,9029748,total clearance,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],24,232163,DB00176,Fluvoxamine
,9029748,half-life,"During fluvoxamine intake, the median of the total clearance of theophylline decreased from 80 ml/min to 24 ml/min, and the half-life increased from 6.6 to 22 h.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,6.6 to 22,232164,DB00176,Fluvoxamine
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],17 to 1.7,232165,DB00176,Fluvoxamine
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],8.9 to 0.9,232166,DB00176,Fluvoxamine
,9029748,partial formation clearances,"The partial formation clearances of the metabolites decreased from 17 to 1.7 ml/min, from 8.9 to 0.9 ml/min, and from 21 to 6.8 ml/min for 1MU, 3MX, and 13DMU, respectively.",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],21 to 6.8,232167,DB00176,Fluvoxamine
,9029748,total,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],84,232168,DB00176,Fluvoxamine
,9029748,total,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],22,232169,DB00176,Fluvoxamine
,9029748,partial clearances,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],9.4,232170,DB00176,Fluvoxamine
,9029748,partial clearances,"During griseofulvin ingestion, the median of the total and partial clearances of theophylline were 84 ml/min, 22 ml/min (1MU), 9.4 ml/min (3MX), and 25 ml/min (13DMU).",Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),[ml] / [min],25,232171,DB00176,Fluvoxamine
,9029748,half-life,The half-life decreased significantly from 6.6 to 5.7 h.,Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,6.6,232172,DB00176,Fluvoxamine
,9029748,half-life,The half-life decreased significantly from 6.6 to 5.7 h.,Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029748/),h,5.7,232173,DB00176,Fluvoxamine
,10349045,brain volume of distribution,"Applying the model, brain volume of distribution (1.12 L/kg +/- 0.2 SEM) and clearance (1.01 L/hour +/- 0.12 SEM) were calculated for fluvoxamine.",Characterization of human brain pharmacokinetics using a two-compartment model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349045/),[l] / [kg],1.12,240755,DB00176,Fluvoxamine
,10349045,clearance,"Applying the model, brain volume of distribution (1.12 L/kg +/- 0.2 SEM) and clearance (1.01 L/hour +/- 0.12 SEM) were calculated for fluvoxamine.",Characterization of human brain pharmacokinetics using a two-compartment model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349045/),[l] / [h],1.01,240756,DB00176,Fluvoxamine
,10349045,bioavailability,The bioavailability of fluvoxamine to the brain from plasma was 1.85 +/- 0.23 SEM.,Characterization of human brain pharmacokinetics using a two-compartment model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10349045/),,1.85,240757,DB00176,Fluvoxamine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],8.7,247154,DB00176,Fluvoxamine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],6.0,247155,DB00176,Fluvoxamine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247156,DB00176,Fluvoxamine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],19,247157,DB00176,Fluvoxamine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247158,DB00176,Fluvoxamine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],30,247159,DB00176,Fluvoxamine
,16918719,t1/2,"Fluvoxamine alone had no statistically significant effect on the half-life of lidocaine (t1/2), but during the combination phase t1/2 (3.8 hr) was significantly longer than during the placebo phase (2.4 hr; P<0.01).",Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918719/),h,3.8,253817,DB00176,Fluvoxamine
,16918719,t1/2,"Fluvoxamine alone had no statistically significant effect on the half-life of lidocaine (t1/2), but during the combination phase t1/2 (3.8 hr) was significantly longer than during the placebo phase (2.4 hr; P<0.01).",Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918719/),h,2.4,253818,DB00176,Fluvoxamine
,16778712,total area under the plasma concentration-time curve,"Caffeine significantly decreased the plasma concentrations at 6 time points (P<0.05) and total area under the plasma concentration-time curve (156.5+/-51.7 vs. 118.9+/-38.2 ng/h/mL, P<0.01) of FLV.",Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778712/),[ng] / [h·ml],156.5,256167,DB00176,Fluvoxamine
,16778712,total area under the plasma concentration-time curve,"Caffeine significantly decreased the plasma concentrations at 6 time points (P<0.05) and total area under the plasma concentration-time curve (156.5+/-51.7 vs. 118.9+/-38.2 ng/h/mL, P<0.01) of FLV.",Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778712/),[ng] / [h·ml],118.9,256168,DB00176,Fluvoxamine
,9517369,elimination half-life,"The elimination half-life based upon the serum concentrations 12-48 h after discontinuation of fluvoxamine was 32.1 +/- 11.0 h whereas the half-life based upon the concentrations 3-7 days after discontinuation was significantly shorter, 15.8 +/- 4.2h (means +/- s.d.; P < 0.001).",Non-linear fluvoxamine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517369/),h,32.1,260081,DB00176,Fluvoxamine
,9517369,half-life,"The elimination half-life based upon the serum concentrations 12-48 h after discontinuation of fluvoxamine was 32.1 +/- 11.0 h whereas the half-life based upon the concentrations 3-7 days after discontinuation was significantly shorter, 15.8 +/- 4.2h (means +/- s.d.; P < 0.001).",Non-linear fluvoxamine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517369/),h,15.8,260082,DB00176,Fluvoxamine
,33677821,absorption rate constant (Ka),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),1/[h],0.30,265598,DB00176,Fluvoxamine
,33677821,apparent clearance (CL/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),[l] / [h],12.88,265599,DB00176,Fluvoxamine
,33677821,apparent distribution volume (V/F),"Typical estimates for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) were 0.30 h-1, 12.88 L/h, and 754.41 L, respectively.","The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33677821/),l,754.41,265600,DB00176,Fluvoxamine
,15025747,peak concentration (C(max)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],900,265619,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],1481,265620,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,0.6,265621,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],1648,265622,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],4225,265623,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[ng] / [ml],2991,265624,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),[h·ng] / [ml],11537,265625,DB00176,Fluvoxamine
,15025747,"under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))","During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,2.8,265626,DB00176,Fluvoxamine
,15025747,elimination half-life (t(1/2)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,0.6,265627,DB00176,Fluvoxamine
,15025747,elimination half-life (t(1/2)),"During placebo administration, geometric means of peak concentration (C(max)), under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h)) and elimination half-life (t(1/2)) of omeprazole were 900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h in homozygous EMs, 1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h in heterozygous EMs, and 2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h in PMs, respectively.",Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025747/),h,2.8,265628,DB00176,Fluvoxamine
,15856488,Retention times,"Retention times of FLU and an internal standard (propafenone) derivative were 15.5 and 13.5 min, respectively.","Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856488/),min,15.5,265649,DB00176,Fluvoxamine
,15856488,Retention times,"Retention times of FLU and an internal standard (propafenone) derivative were 15.5 and 13.5 min, respectively.","Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856488/),min,13.5,265650,DB00176,Fluvoxamine
<,34432364,area under the concentration-time curve ratio [AUCR],"Simulations of untested scenarios revealed an absence of drug-drug interaction (DDI) risk between remibrutinib and the weak CYP3A4 inhibitor fluvoxamine (area under the concentration-time curve ratio [AUCR] <1.25), and a moderate effect with the CYP3A4 inhibitor erythromycin (AUCR: 2.71).",Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),,1.25,265863,DB00176,Fluvoxamine
,34432364,AUCR,"Simulations of untested scenarios revealed an absence of drug-drug interaction (DDI) risk between remibrutinib and the weak CYP3A4 inhibitor fluvoxamine (area under the concentration-time curve ratio [AUCR] <1.25), and a moderate effect with the CYP3A4 inhibitor erythromycin (AUCR: 2.71).",Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),,2.71,265864,DB00176,Fluvoxamine
,34432364,Oral bioavailability,Oral bioavailability of remibrutinib was 34%.,Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),%,34,265865,DB00176,Fluvoxamine
,7955810,peak plasma diazepam concentrations,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ng] / [ml],108 to 143,272077,DB00176,Fluvoxamine
,7955810,apparent oral diazepam clearance,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ml] / [kg·min],0.,272078,DB00176,Fluvoxamine
,7955810,apparent oral diazepam clearance,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ml] / [kg·min],0,272079,DB00176,Fluvoxamine
,7955810,half-life,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,51 to 118,272080,DB00176,Fluvoxamine
,7955810,time required,"Although peak plasma N-desmethyldiazepam levels were similar in the two sessions, the time required for the metabolite to reach a peak was longer during fluvoxamine intake than in the control session (206 versus 62 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,206,272081,DB00176,Fluvoxamine
,7955810,time required,"Although peak plasma N-desmethyldiazepam levels were similar in the two sessions, the time required for the metabolite to reach a peak was longer during fluvoxamine intake than in the control session (206 versus 62 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,62,272082,DB00176,Fluvoxamine
